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Antimicrobial resistance in Neisseria gonorrhoeae is of significant public health concern and 
treatment options beyond current first-line therapies are limited.1 Effective surveillance of 
antimicrobial resistance in this organism is imperative to retain N. gonorrhoeae as a treatable 
disease.2  
PHE’s Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) is a sentinel 
surveillance programme, which tests consecutive N. gonorrhoeae isolates from 26 sexual health 
clinics across England and Wales, collected over a two- to three-month period. Isolates are tested 
against seven different antimicrobials, specifically penicillin, tetracycline, ciprofloxacin, cefixime, 
ceftriaxone, azithromycin and spectinomycin.  
High-level tetracycline resistance (MICs ≥16 mg/L) 3 emerged in the species in the mid-1980s with 
the insertion of the tet(M) resistance gene into two N. gonorrhoeae conjugative plasmids,4 a 42.8 Kb  
‘American’ plasmid and a 40.5 Kb ‘Dutch’ plasmid.5 The tet(M) product confers resistance to 
tetracycline by binding to the 30S bacterial ribosomal sub-unit, resulting in release of tetracycline 
and the continuation of protein synthesis.6 Lower level tetracycline resistance (>1 mg/L but ≤8 mg/L) 
in N. gonorrhoeae is considered to be chromosomally mediated.6 We sought to investigate the 
validity of these criteria for segregating isolates with chromosomal and plasmid-mediated 
tetracycline resistance and, specifically, whether some tet(M)-containing strains might not express 
high-level resistance leading to under-recognition.  
One hundred and ninety-one N. gonorrhoeae isolates with known tetracycline susceptibility profiles 
(MICs ranging from ≤0.5 mg/L to ≥16 mg/L) were selected according to tetracycline MIC from those 
submitted to PHE as part of GRASP between 2015 and 2017.  Susceptibilities had been determined 
by agar dilution using breakpoint plates with 1 mg/L and 8 mg/L of tetracycline in DST agar [HiMedia, 
India] plus 1% Vitox [Oxoid, SR0090H} and 5% lysed horse blood (TCS Biosciences, HB038] and/or by 
gradient strip testing (Etest® [bioMerieux, France] on GC agar base [Difco, 228950] plus 1% Vitox). 
Boilates were used as template for PCR targeting the tet(M) genes of the American and Dutch 
plasmids specifically.7 Isolates were scored on the presence/absence and size of any amplicon 
(American plasmid: 778 bp, Dutch plasmid: 443 bp). 
All isolates (n=105) with tetracycline MICs ≥16 mg/L were positive for either an American or Dutch 
tet(M) conjugative plasmid. Furthermore, no isolates (n=86) with MICs ≤8 mg/L harboured either 
plasmid. As expected the American plasmid predominated in the isolate panel selected, accounting 
for 76.2% of the high-level tetracycline resistance plasmids detected.  
Subsequent analysis found that whilst all tetracycline resistance (>1 mg/L) was more likely to be 
found in isolates from MSM compared with heterosexual men (adjusted odds ratio (AOR) 1.39 [95% 
confidence interval (CI) 1.18-1.64], P<0.001), isolates with high-level resistance (≥16 mg/L) were 
more likely to be from heterosexual men compared with MSM (AOR: 1.45 [95% CI: 1.11-1.88], 
p=0.006) (Table 1). 
Between 2015 and 2017, GRASP data revealed a year-on-year increase in the proportion of N. 
gonorrhoeae isolates that were resistant to tetracycline, from 39.4% in 2015 to 48.5% in 2017.2 
Using the confirmed correlation between MIC and presence of tet(M), we can infer a simultaneous 
increase in the proportion of isolates with plasmid-mediated tetracycline resistance (30.1% in 2015, 
41.7% in 2016 and 52.7% in 2017), which may reflect increased use of doxycycline to treat other 
sexually transmitted infections (STIs), such as Chlamydia trachomatis during this period.8  
Furthermore, the potential use of doxycycline as post-exposure prophylaxis for STIs in MSM in the 
era of HIV pre-exposure prophylaxis (PrEP) is of public health concern.9 Taken together, these 
developments highlight the perilous situation of antimicrobial resistance in N. gonorrhoeae. 
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Table.  Analysis of likelihood of infection with tetracycline resistant (>1 mg/L) or high-level 
tetracycline resistant (≥16 mg/L) N. gonorrhoeae by gender and sexual orientation (cells in bold 
indicate statistical significance)  
 Outcome: tetracycline resistance (>1mg/L) compared to 




























Total  4,251   1,810  42.6%  
Year 
2015 1,699 670 39.4%  1.00  - - - 
 
1.0
0  - - - 














Sexual orientation and gender 








men 730 282 38.6%  1.00  - - - 
 
1.0
0  - - - 







Unknown 95 44 46.3%  
 
Outcome: high-level tetracycline resistance (MIC ≥16 































Total  1,810  745 41.2%  
Year 
2015 670 202 30.1%  1.00  - - - 
 
1.0
0  - - - 














Sexual orientation and gender 
MSM 1,356 529 39.0%  1.00  - - - 
 
1.0
0  - - - 
Heterosexual 














Unknown 44 25 56.8%  
COR - crude 
odds ratio            
AOR - adjusted odds ratio           
L/U CI - lower/upper 95% 
confidence interval           
 
